The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
 
David Lawrence Bajor
Consulting or Advisory Role - Avoro Capital Advisors; BridgeBio Pharma; Cardinal Health; Tempus
Research Funding - Apexigen (Inst); Bristol-Myers Squibb/Celgene (Inst); Calithera Biosciences (Inst); GlaxoSmithKline (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Tesaro (Inst)
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Honoraria - Foundation Medicine; Guardant Health
Consulting or Advisory Role - Eisai
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Fate Therapeutics (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Vedanta Biosciences (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Gina M. Vaccaro
Consulting or Advisory Role - Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Exelixis; Incyte; MSD; Pfizer; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - Incyte
Research Funding - Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; E.R. Squibb Sons, LLC; Eisai; Foundation Medicine
 
Ashiq Masood
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Exelixis (Inst); Genentech/Roche (Inst); Ipsen (Inst); Macrogenics (Inst); Merck (Inst); Novocure (Inst); PRA Health (Inst); Proteus Digital Health (Inst); Seagen (Inst); SIGNATERA (Inst); Tempus
 
Ursa Brown-Glaberman
Consulting or Advisory Role - Biotheranostics; Eisai; Novartis; Seagen; Taiho Oncology
Research Funding - Seagen (Inst)
 
Juneko E. Grilley-Olson
Consulting or Advisory Role - Bayer; Chimerix; Kura Oncology; SpringWorks Therapeutics
Research Funding - Astellas Pharma (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Loxo (Inst); NanoCarrier (Inst); Pfizer (Inst); Seagen (Inst)
 
Hedy L. Kindler
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Deciphera; Inhibrx; Novocure; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Deciphera (Inst); Fibrogen (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Polaris (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); Verastem (Inst); Vivace Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Seagen
 
Elisabeth I. Heath
Honoraria - AstraZeneca; Bayer; Dendreon; Sanofi; Seagen
Consulting or Advisory Role - Agensys; AstraZeneca; Bayer; Dendreon; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Agensys; Bayer; Sanofi
Other Relationship - Caris Centers of Excellence
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Synologic Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst)
 
Peigen Zhou
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Travel, Accommodations, Expenses - Seagen
 
Hailing Lu
No Relationships to Disclose
 
Sahar Ansari
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Jonathan Hayman
Employment - Seagen
 
Michael W. Schmitt
Employment - Seagen
Stock and Other Ownership Interests - Seagen; TwinStrand Biosciences
Patents, Royalties, Other Intellectual Property - Inventor on patents relating to high accuracy DNA sequencing held by the University of Washington, with an associated revenue sharing agreement.
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme